The results of hepatoblastoma treatment at the national hospital of pediatrics

Downloads

Download data is not yet available.
PDF (Tiếng Việt)     80    68

Abstract

Objectives: To evaluate the results of hepatoblastoma treatment and the advances in the application of protocol SIOPEL 3 at the National Hospital of Pediatrics. Methods: descriptive cross-sectional series, longitudinal study with heptatoblastoma patients from 0 to 16 years old treated at the National Hospital of Pediatrics. Results: During the period from 01/01/2010 12/31/2013 at the National Hospital of Pediatrics, 46 hepatoblastoma patients were treated with protocol SIOPEL 3. Overall survival rate was 82.6% after the average follow-up period of 29.6 ± 15.3 months. Standard risk group had 3 year event-free survival of 89.1%, high risk group of 21.4%. Relapsed rate was 6.5% and the mortality rate was 17.4% due to progressive disease. Conclusion: hepatoblastoma is sensitive to chemicals, treatment outcomes for hepatoblastoma patients has made progress, particularly in standard risk group        
https://doi.org/10.38103.28.10

References

Malogolowkin MH, K.H., Meyers RL, Krailo MD, Rowland JM, Haas J, Finegold MJ. (2011), Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group, Journal of Clinical Oncology, 29, pp. 3301-3306,

Joerg Fuchs, G.S., Rupert Handgretinger Steven W Warmann (2012), Extanded hepatic resection in advanced hepatoblastoma, Frontiers in Bioscience, E4, pp. 462-467.

Otte, J.-B. (2010), Progress in the surgical treatment of malignant liver tumors in children, Cancer Treatment Reviews, 36, pp. 360-371.

Trần Đức Hậu, PTL, TTH và cs (2007), Kết quả điều trị U nguyên bào gan tại khoa Ung bướu, Bệnh viện Nhi Trung ương từ 2002 - 2006, Tạp chỉ Nhi khoa, 15(1), pp. 46-54.

Zrioz J., Maibach R., Shafford E. et al. (2010), Successful Treatment of Chilhood High- risk Hepatoblastoma with Dose Intensive Multiagent Chemotherapy and Surgery: Final Results of the SIOPEL-3HR Study, Journal of Clinical Oncology, 29(15), pp. 2584-2590.

Perilongo G, Maibach R, Shafford E. et al (2008), Cisplatin versus Cisplatin plus Doxorubicin for Standard risk Hepatoblastoma, The New England Journal of Medicine, 361(7), pp. 1662-1670.

Otte Jean Bernard (2010), Progress in the surgical treatment of malignant liver tumors in children, Cancer Treatment Reviews, 36. pp. 360-371.

Published 03-03-2025
Fulltext
PDF (Tiếng Việt)     80    68
Language
Issue No. 28 (2015)
Section Original article
DOI 10.38103.28.10
Keywords hepatoblastoma

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital

Tuyet Lan, P., & Thi Thuy Dung, L. (2025). The results of hepatoblastoma treatment at the national hospital of pediatrics. Journal of Clinical Medicine Hue Central Hospital, 7(28), 17–22. https://doi.org/10.38103.28.10